MajorClass III antiarrhythmic×Atypical antipsychotic – thienobenzodiazepine
Updated · Methodology
Mechanism
Dronedarone can moderately prolong the Bazett heart-rate-corrected QT interval (QTc), by about 10 ms (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label estimates a 15 ms increase at 400 mg twice daily with food (dronedarone label, US Food and Drug Administration, FDA). Because of the risk of proarrhythmia, both dronedarone documents contraindicate dronedarone with drugs that can induce torsade de pointes. Their examples are phenothiazines, tricyclic antidepressants, certain macrolides and class I and III antiarrhythmics, and olanzapine is not among them (EMA, FDA). In olanzapine clinical trials, clinically significant QTc prolongation (Fridericia-corrected QTc of 500 ms or more with a baseline below 500 ms) was uncommon, at 0.1–1% of patients. Olanzapine did not differ significantly from placebo in associated cardiac events. According to the US label, the proportion of patients with potentially important QT and QTc changes did not differ from placebo either (olanzapine SmPC, EMA; olanzapine label, FDA). The documents describe no pharmacokinetic interaction. In the liver, olanzapine undergoes conjugation and oxidation involving CYP1A2 and CYP2D6. The CYP2D6 inhibitor fluoxetine did not significantly change its pharmacokinetics, and dronedarone does not significantly inhibit CYP1A2 (olanzapine and dronedarone SmPCs, EMA).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Adverse reactions of olanzapine include a slow heart rate, prolongation of the heart-rate-corrected QT interval, ventricular tachycardia and fibrillation, and sudden death (olanzapine summary of product characteristics, SmPC, European Medicines Agency, EMA). After marketing, sudden cardiac death was reported in people taking olanzapine. In a retrospective observational cohort study, the risk of presumed sudden cardiac death was about twice that in people not taking antipsychotics (EMA). Adverse reactions of dronedarone include a slow heart rate and prolongation of the heart-rate-corrected QT interval. A proarrhythmic effect is possible with drugs that promote arrhythmias and with electrolyte disorders (dronedarone SmPC, EMA).
Management
Avoid the combination. Both dronedarone documents contraindicate dronedarone with drugs that prolong the QT interval and can induce torsade de pointes (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA; dronedarone label, US Food and Drug Administration, FDA). Olanzapine is not among the examples, and its own documents do not mention torsade de pointes. In trials, clinically significant prolongation of the heart-rate-corrected QT interval (QTc) was uncommon, and olanzapine did not differ significantly from placebo in associated cardiac events (olanzapine SmPC, EMA; olanzapine label, FDA). For these reasons, the editors do not classify the combination as contraindicated. Use olanzapine with caution together with QTc-prolonging drugs, especially in older people and in congenital long QT syndrome, congestive heart failure, cardiac hypertrophy, low potassium or low magnesium (olanzapine SmPC, EMA). Dronedarone prolongs QTc according to its own documents (EMA, FDA). Dronedarone is also contraindicated with a heart rate below 50 beats per minute and with a Bazett QTc of 500 ms or more. If any of its contraindications develops during treatment, dronedarone is stopped (EMA). Potassium or magnesium deficiency is corrected before dronedarone is started and during treatment. Monitoring, including an electrocardiogram (ECG), is recommended during treatment, and dronedarone is stopped if the QTc is 500 ms or more (EMA). No document sets an interval between stopping one drug and starting the other. Dronedarone and its metabolite are fully cleared from plasma 2 weeks after stopping. The mean half-life of olanzapine in healthy volunteers is about 34 hours in younger people and about 52 hours in people aged 65 and over (dronedarone and olanzapine SmPCs, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zyprexa (olanzapine) prescribing information (2009)
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Olanzapina (EU/1/99/125), sección 4.4 (2026)– EMA, Zyprexa Velotab 10 mg comprimidos bucodispersables (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 99125002, consultada 10/2026, secciones 4.3, 4.4, 4.5, 4.8 y 5.2